Avances clínicos recientes | 28 JUN 04

Manejo de la diarrea infecciosa

La diarrea infecciosa es la causa más común de diarrea en todo el mundo y la enfermedad diarréica es la segunda causa mundial más importante de muerte.
Autor: Dres. Casburn-Jones AC, Farthing MJ Fuente: Department of Gastroenterology, University college Hospital; St. George´s Hospital Medical School. Londres. Reino Unido.  Gut. 2004 Feb;53(2):296-305.
1. WheelerJG, Sethi D, Cowden JM, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and report  to national surveiIlance. BMJ 1999;318:1046-305.
2. Farthing MJG. Infectious diarrhea. In: Irvine E J, Hunt RH, eds. Evidence-based gastroenterology. Canada: BC Decker, 2001:323-41.
3. Farthing MUG. Pathophysiology of infectlve diarrhoea. Eur J Gastroenterol Hepat ol 1993;5:796-807.
4. Cassuto J, Jodal M, Tutfle R, et al. 5-Hydroxytryptamine and cholera secretic .Physiological and pharmacological studies in cats and rats. Scand J Gastroenterol 1982; 17:695-703.
5. Cassuto J, Fahrenburg J, Jodal M, et al. Release of vasoactive intestinal polypeptide from the cat of the small intestine exposed to cholera toxin. Gut 1981;22:958-63.
6. Beubler E, Horina G. 5-HT2 and 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid  secretion in the rat. Gastroenterology 1990;99:83-9.
7. Turvill JL, Farthing MJG. Effect of granisetron on cholera toxin-induced enteric secretion. Lancet  1997;349:1293.
8. Turvill JL, Connor P, Farthing MJG. Neurokinin 1 and 2 receptors mediate cholera toxin secretion in rat  jejunum. GastroenterologX 2000;119:1037-44
9. Banks MR, Casburn-Jones AC, Farthing MJG. Cholera toxin (CI) Escherichia coli heat lablie toxin (LT) and heat stable toxin (STa) have an indirect effect on dislal intestinal fluid transport in the rat small intestine. Gut 2002;50(suppl II):A69.
10. Nocerino A, lafusco M, Guandalini S. Cholera toxin-induced small intestinal secretion has a secretoff effect on the colon of the rat. Gastroenterology, 1995;108:34.
11. Tunvill JL, Mourad FH, Farthing MJG. Crucial role for 5-HT in cholera toxin but not Escherichia colt heat-labile nterotoxin-intesfinal secretion in rats. Gastroenterology 1998; 115:883-90.
12. Lundgren O, Pergrin AT, Person K, etal. Role of the enteric nervous system in the fluid and electrolyte secretion of ratavirus diarrhea. Science 200, 287:491-5.
13. Farthing MJG. Acute diarrhoea: pathophysiology. In: Gracey M, Walker-Smith JA, eds. DiarrhoeaJ disease. Philadelphia, PA: Vevey/Lippincott-Raven Publishers, 1997;38:55-71.
14. Farthing MJG. Dehydration and rehydration in children. In: Arnaud MJ ed. Hydration throughout life. Paris: John Libbey Eurotext, 1998:159-73.
15. Nostrant l-r, Kumar NB, Appelman HD. Histopathology differentiates acute self  limited colitis from ulcerafive colitis. Gastroenterology 1987;92:318-28.
16. Allison MC, Hamilton-Dutoit S J, Dhillon AP, et al. The value of rectal biopsy in distinguishing self-limiting colitis from early inflammatory bowel disease. QJM 1987;65:985 -95.
17. International Study Group on Reduced-Osmolality ORS Solutions. Muhlcentre evaluation of reduced-osmolality oral rehydration salts solution. Lancet 1995;346:282-5.
18. Thillainayagam AV, Hunt JB, Farthing MJG. Enhancing clinical efficacy of oral rehydration therapy: is low  osmolality the key? Gastraenteralogy 1998;114:197-210.
19. Gore SM, Fontaine O, Pierce NF. Impact or rice-based oral rehydration solution on stool output and duration of diarrhoea: meta-analysis of 13 clinical trials. BMJ 1992;304:287-91.
20. Ramakrishna BS, Venkataraman S, Srinivasan P, et al. Amylase resistant starch plus oral rehydration solution for cholera. N Engl J Med 2000;342:308-13.
21. Bowie MD, Hill ID, Mann MD. Loperamide for treatment of acute diarrhoea in infants and young children. A double-blind placebo-controlled trial. S Afr med J 1995;85:885-7.
22. Kaplan MA, Prior M J, McKonly KI, et al. A multicentre randomised controlled trial of a liquid loperamide product versus plcebo in the treatment of acute diarrhoea in children. Cfin Pediatr 1999;38:579-91.
23. Ericsson CD, Nicholls Vasquez l, DuPont HL, et al. Optimal dosing of trimethoprim-suJfamethoxazol when used with loperamide to treat traveler's diarrhoea. Antimicrob Agents Chemother 1992;36:2821-4.
24. Murphy GS, Bodhidatta L, Echoraffia P, et al. Ciprofioxacin and loperamide in the treatment of bacillary  dysentery. Ann Intern Mad 1993;118:582-6.
25. Taylor DN, Sanchez JL, Candler W, etal. Treatment of traveler's diarrhoea: ciprofioxacin plus Ioperamide compared with ciprofloxacin alone. A  placebo randomized control trial Ann Intern Mad 1991 ;114:731-9.
26. Pawell DW, Field M. Pharmacological approaches to treatment of secretary dlarrhoea. In: Field M, Fordtran JS, Schultz SG, ads. 5acretory diarrhoea. Bethesda, MD: American Physiological Society, 1980:187-209.
27. Farthing MJG, Cashurn-Jones A, Banks MR. Getting control of intestinal secretion: thoughts for 2003. Dig Liv Dis 2003;35:378-85.
28. Silberschmidt G, Schik. MT, Steffen R, et al. Treatment of travelers' diarrhoea: zaldaride compared with  Ioperamide and placebo.  Eur J Gastroenterol Hepatol 1995;7:871-5.   
29. Okhuysen PC, DuPont HL, Ericsson CD, et al. Zaldaride maleate (a new calmodulin antagonist) versus Ioperamide in the treatment of traveler's diarrhoea: a randomised, placebo-controlled trial. Clin Infect Dis   1995;21:341-4.
30. Farthing M. IG. Novel targets for the control of secretary diarrhoea. Gut  2002;50JsuppJ III):iii l 5-18.
31. Turvil, JL, Farthing MJG. Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport. Eur J Gastroenterol Hepatol 1997;9:877-80.
32. Farthing MJG. Enkephalinase inhibition: a rationale approach to antisecretary therapy for acute diarrhoea. Ailment Pharmacol Ther 1999; 13(suppl  6):1-2.
33. Satazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, etal. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000;343:463-7.
34. Cezard JP, Duhamel JF, Meyer M, et al. Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenteralogy 2001; 120:799-805.
35. Ma T, Thiagarajah JR, Yon H, et al. Thiazilinone CFTR inhibitor identified by high throughout screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002;110:1651-8.
36. DiCesare D, DuPont HL, Mathewson J J, et al. A double-blind, randomized, placebo-controlled study of SP 303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol 2002;97: 2585-8.
37. Dupont HL, Ericcson C. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993;328:1821-7.
38. Grbach SL Bismuth therapy in gastro-intestinal diseases. Gastroenteralogy 1990;99:863-75.
39. Ericsson CD, Johnson PC, DuPont HL, et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy  for traveler's diarrhea. A placebo controlled randomized trial. Ann Intern Med 1987;106:216-20.
40. Mattila L, Peltola H, Siitonen A, et al Short-term treatment of traveler's diarrhea with norfioxacin: a double-blind, placebo-controlled study during two sessions. Clin Infect Dis 1993;17:779-82.
41. Salam I, Katelaris P, Lei h-Smith S, et al. A randomised placebo-controlled trial of single dose ciprofloxacin in treatment of travellars' diarrhoea. Lancet 1994;344:1537-9.
42. D)uPont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: A randomised, double-blind clinical trial. Clin Infect Dis 2001 ;33:1807-15.
43. Dutta D, Bhattacharya SK, Bhattacha a MK, et al. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae 0139 infection. J Antimicrob Chemother 1996;37:575-81.
44. Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofioxocin and doxycytine for cholera caused by Vibrio cholerae 01 or 0139. Lancet 1996;348:296-300.
45. Usubutun S, Agalar C, Dirt C, et aL Single dose ciprofloxacin in cholera. Rue J Emerg Med 1997;4:145-9.
46. Gorbach SL. The discovery of Lactobacillus GG. Nutr Today 1996;31~2S-4.
47. Guandalini S, Kirjavainen PV, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhoea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000;30:54-60.
48. Huang JS, Bousvaros A, Lee JW, et al. Efficacy of probiotic use in acute diarrhea in children: A meta-analysis. Dig Dis Sci 2002;47:2625-34.
49. D´Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: Metaanalysis. BMJ 2002;324:1361-4.
50. Tauxe RV, Puhr ND, Wells JG, et al/. Antimicrobial resistance of Shigella isolates in the USA: the importance of international travellers. J Infect Dis 1990;162:1107-11.
51. Bennish ML, Solam MA, Haider R, et al. Therapy for shigelliosis. Il. Randomized double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990;162:711-16.
52. Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomised, controlled trial. Ann Intern Med 1997;126:697-703.
53. Bassil S, Hyams KG, El-Masry NA, et aL Short-course norfioxacln and trimethYoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt. Am J Trap Med Hyg 1994;51:219-23.
54. Gotuzzo E, Oberhelman RA, Maguina C, et al. Comparison of single-dose treatment with narfioxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigelJosis in adults. Antimicrab Agents Chemother 1989;33:1101-4.
55. Bennish ML, Salam MA, Khan WA, etal. Treatment of shigellosis Ill. Comparison of one or two-dose  ciprofioxacin with standard 5 day therapy. A randomised, blinded trial Ann Intern Med 1992; 117:727-34.
56. Andors B J, Lauer BA, Paisley JW, et aL Double-blind placebo controlled trial of erythromycin fro treatment of Campylobacter enteriris. Lancet 1982;1:131-2.
57. Mandal BK, Ellis ME, Dunbar EM, et al. Double-blind placebo-controlled trial of erythrom dn in the treatment of ciinicaJ campyJobacter infection. J Antimlcrob Chemother 1984;13:619-23.
58. Salazar-Lindo E, Sack RB, Chea-Woo E, et al. Early treatment with erythromycin of Campylobacter jejunie associated dysentery in children. J Pediatr 1986; 109: 355-60.
59. Williams MD, Scborling JB, Barrett IJ, et al. Early treatment of Campylobacter jejuni enteritis. Antimicrob Agents Chemother 1989;33:248-50.
60. Gayraud M, Scavizzi MR, Mollaret HJH, etal. Antibiotic treatment of Yersinia enterocolitica septicaemia: a retrospective review of 43 cases. Clin Infect Dis 1993; 17:405-10.
61. Crowe M, Ashford K, Isaphani P. Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica. J Med Microbiol 1996;45:302-9.
62. Teaslay DG, Gerding DN, Olson MM, et al. Prospective randomlsed trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2:1043-6.
63. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Cheroother 1995;35:673-9.
64. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin and bacitracin. Gastroenterology 1985;89:1038-45.
65. Wenisch C, Parschalk B, Hasenhundl M, et al Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium  difficile-associated diarrhea. Clin Infect Dis 1996;22:813-18.
66. Kell MP, Farthing MJG. Infections of the gastrointesfinal tract. In: O'Grady F, Lambert HP, Finch RG, et al. eds. Antibiotic and chemotherapy, 7th edn. London: Churchill Livingstone, 1997:708-20.
67. Garcia-Laverde A, de Banilia L. Clinical trials with metronidazole in human balantidiasis. Am J Trap Med Hyg 1975;24:781-3.
68. Prouix F, Turgeon JPJ, Delage G, et el. Randomized, controlled trial of antibiotic therapy for Escherichia colt O157-H7 enteriris. J Pediatr 1992; 121:299-303.
69. Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157-H7-associated haemorrhogic coliris in a nursing home. N Engl J Med 1987;317:496-500.
70. Pavia AT, Nichols CR, Green DP, etal. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157-H7 infections in institutions for mental retarded persons: clinical and epidemiologic observations. J Pediatr 1990;116:544-51.
71. Bissuel F, Cotte L, Rabodonirina M, etal. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin Infect Dis 1994; 18:447-9.
72. Farthing MJG. Clinical aspects of human cryptosporidiosis. Cantrib Microbiol 2000;6:50-74.
73. Mollna JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encepha)itozoon intestinalis in patients  with AIDS: a rondoraised double-blind trial. J Infect Dis 1998;177:1373-7.
74. Leder K, Ryan N, Spelman D, et al. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998;30:331-8.
75. Anwar-Bruni DM, Hogan SE, Schwartz DA, et al, Atova uone is effective treatment for the symptoms of  gastrointestinal microsporidiasis in HIV- 1 infected patients. AIDS 1996;10:619-23.
76. Dionisio D, Sterrantino G, Meli M, etal. Use of furazofidone for the treatment of microsporidiosis due to Enterocytozoon bieneusi in patients with AIDS. Recent Prag Mad 1995;86:394-7.
77. Dionisio D, Manneschi LI, Di Lollo S, etal. Persistent damage to Enterocytozoon bieneusi with ersistent symptomatic relief after combined furazolidone and albendazole in AIDS patients. J Clin Pathol 1998;51:731-6.
78. Sharpstone D, Rowbottom A, Francis N, etal. Thalidomide: a novel therapy for m icrosporidlosis.  Gastroenterology 1997; 1 ! 2:1823-9.
79. Hoge CW, Shlim DR, Ghimire M, et el. Placebo-controlled trial of cotrimoxazole for Cyclospora infections amang travailors and foreign residents in Nepal. Lancet 1995;345:691-3.
80. Vesy C J, Paterson WL Review article: the management of giardiasis. Ailment Pharmacol Thor 1999; 13:843-50.


Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2018